Suman Suresh Kuppahally, MD
Cardiovascular Disease (Cardiology) · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Offices
- 2
Offices
2 locations
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kuppahally’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A72494 · Current
Licensed to practise in California · since 2000 · expires 2028-04-30 · Nagpur University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$823,881
Medicare paid this office $823,881 for 979 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 807 | $221,614 | $107 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 138 | $203,594 | $1,475 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 138 | $105,590 | $383 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 423 | $79,540 | $185 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 75 | $63,752 | $850 |
See all 27 services
| Return visit (30+ min) | 807 | $221,614 | $107 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 138 | $203,594 | $1,475 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 138 | $105,590 | $383 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 423 | $79,540 | $185 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 75 | $63,752 | $850 |
| New patient visit (60+ min) | 121 | $21,629 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $20,553 | $66 |
| Critical care, first 30-74 minutes | 37 | $20,186 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $13,817 | $144 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 27 | $11,800 | $437 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 172 | $11,505 | $67 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 124 | $7,497 | $56 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 68 | $4,491 | $21 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 27 | $4,479 | $83 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 62 | $4,319 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 261 | $3,989 | $12 |
| Anticoagulant management of patient taking warfarin | 23 | $2,864 | $10 |
| Injection, regadenoson, 0.1 mg | 142 | $2,845 | None |
| Programming of dual lead pacemaker system | 26 | $2,331 | $73 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,491 | $83 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 72 | $1,467 | $20 |
| Short return visit (20+ min) | 17 | $1,403 | $78 |
| External shock to heart to regulate heart beat | 15 | $1,369 | $91 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | $1,117 | $22 |
| Infusion, normal saline solution, 250 cc | 138 | $566 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 27 | $378 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $267 | $15 |
Who their Medicare patients are
979 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 28% · Women 58% · Also on Medicaid 9% · Health risk score 1.41. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 44% · Atrial fibrillation 35% · Heart failure 33% · Diabetes 30% · Chronic kidney disease 27% · Cancer 20% · Depression 17% · Stroke 16% · COPD 15% · Dementia 12%.
The office billed $2,156,780, Medicare allowed $1,081,749 and paid $823,881; for 7,091 services of 43 kinds; $3,411 of it was for drugs given in the office and $820,469 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 979 | 7,091 | 79 | 1.41 | $2,156,780 | $823,881 |
| 2023 | 1,000 | 8,838 | 79 | 1.41 | $1,785,454 | $729,590 |
| 2022 | 1,014 | 10,964 | 79 | 1.49 | $1,880,188 | $796,446 |
| 2021 | 1,015 | 11,604 | 79 | 1.43 | $1,905,518 | $868,434 |
| 2020 | 976 | 5,671 | 79 | 1.52 | $1,103,889 | $493,919 |
| 2019 | 1,087 | 5,360 | 78 | 1.57 | $1,108,060 | $494,108 |
| 2018 | 1,050 | 4,985 | 78 | 1.59 | $1,000,153 | $441,805 |
| 2017 | 873 | 3,819 | 78 | 1.61 | $696,953 | $298,331 |
| 2016 | 754 | 3,748 | 78 | 1.71 | $670,734 | $294,781 |
| 2015 | 675 | 3,731 | 78 | 1.71 | $513,898 | $283,892 |
| 2014 | 549 | 4,373 | 78 | 1.62 | $472,280 | $291,286 |
| 2013 | 617 | 4,338 | 78 | 1.50 | $536,913 | $321,576 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Return visit (30+ min) | 779 | $207,407 | $110 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 91 | $143,209 | $1,574 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 428 | $83,721 | $193 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 91 | $73,823 | $408 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 49 | $45,801 | $935 |
| New patient visit (60+ min) | 157 | $29,107 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 124 | $24,082 | $71 |
| Critical care, first 30-74 minutes | 36 | $19,370 | $186 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 109 | $18,311 | $149 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 30 | $13,686 | $456 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $9,753 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 135 | $9,263 | $68 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 30 | $5,996 | $100 |
| Injection, regadenoson, 0.1 mg | 36 | $5,128 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 67 | $4,743 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 59 | $4,415 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 239 | $3,599 | $13 |
| Anticoagulant management of patient taking warfarin | 24 | $3,536 | $10 |
| Programming of dual lead pacemaker system | 32 | $2,875 | $70 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,105 | $96 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 13 | $2,096 | $31 |
| Short return visit (20+ min) | 22 | $1,913 | $83 |
| External shock to heart to regulate heart beat | 14 | $1,673 | $98 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 13 | $1,415 | $22 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 60 | $1,101 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 47 | $1,084 | $23 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $554 | $24 |
| Infusion, normal saline solution, 250 cc | 91 | $366 | None |
| Ultrasound of heart blood flow, valves and chambers | 22 | $353 | $16 |
2022: 31 services
| Return visit (30+ min) | 793 | $229,245 | $112 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 107 | $169,030 | $1,580 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 107 | $87,948 | $411 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 375 | $75,371 | $198 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 57 | $55,098 | $967 |
| New patient visit (60+ min) | 148 | $27,931 | $189 |
| Critical care, first 30-74 minutes | 37 | $25,357 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 112 | $22,561 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 107 | $20,522 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 151 | $9,678 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 133 | $9,239 | $69 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $6,557 | $437 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 316 | $5,096 | $13 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 20 | $5,073 | $254 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 75 | $5,060 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 63 | $4,523 | $25 |
| Programming of dual lead pacemaker system | 42 | $4,333 | $76 |
| Short return visit (20+ min) | 36 | $3,550 | $85 |
| Anticoagulant management of patient taking warfarin | 30 | $3,070 | $10 |
| Long return visit (40+ min) | 21 | $2,929 | $139 |
| External shock to heart to regulate heart beat | 20 | $2,804 | $100 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,162 | $98 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 15 | $1,982 | $66 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 14 | $1,739 | $24 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 99 | $1,715 | None |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 14 | $1,509 | $23 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 59 | $1,377 | $23 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,132 | $31 |
| Infusion, normal saline solution, 250 cc | 107 | $442 | None |
| Ultrasound of heart blood flow, valves and chambers | 21 | $345 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $288 | $22 |
2021: 31 services
| Return visit (30+ min) | 796 | $248,727 | $115 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 117 | $192,830 | $1,648 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 117 | $98,216 | $420 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 434 | $91,553 | $208 |
| New patient visit (60+ min) | 174 | $32,920 | $189 |
| Critical care, first 30-74 minutes | 42 | $29,374 | $196 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 33 | $27,573 | $788 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 117 | $24,643 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 116 | $22,447 | $168 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 186 | $13,592 | $70 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 23 | $11,652 | $507 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 153 | $9,660 | $61 |
| Long return visit (40+ min) | 42 | $7,103 | $165 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 330 | $5,430 | $14 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 74 | $4,965 | $25 |
| Programming of dual lead pacemaker system | 41 | $4,735 | $73 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 23 | $4,414 | $98 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 16 | $4,167 | $260 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 62 | $4,095 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $4,008 | $89 |
| Injection, regadenoson, 0.1 mg | 15 | $2,858 | None |
| External shock to heart to regulate heart beat | 17 | $2,567 | $103 |
| Short return visit (20+ min) | 26 | $2,352 | $87 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 104 | $2,289 | None |
| Anticoagulant management of patient taking warfarin | 33 | $2,001 | $10 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,511 | $101 |
| Programming of single lead pacemaker system | 11 | $1,067 | $63 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $877 | $30 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 29 | $716 | $23 |
| Infusion, normal saline solution, 250 cc | 117 | $517 | None |
| Ultrasound of heart blood flow, valves and chambers | 15 | $253 | $17 |
2020: 33 services
| Return visit (30+ min) | 667 | $146,073 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 269 | $58,576 | $212 |
| New patient visit (60+ min) | 232 | $45,543 | $196 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 24 | $40,199 | $1,675 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $27,750 | $505 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $22,390 | $185 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 24 | $20,209 | $421 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 22 | $17,716 | $770 |
| Long return visit (40+ min) | 91 | $14,611 | $135 |
| Critical care, first 30-74 minutes | 27 | $14,313 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $10,662 | $67 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 54 | $10,177 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $9,358 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 125 | $9,237 | $69 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 109 | $7,615 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 324 | $6,597 | $17 |
| Programming of dual lead pacemaker system | 52 | $5,076 | $69 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $2,630 | $22 |
| Injection, regadenoson, 0.1 mg | 15 | $2,551 | None |
| Short return visit (20+ min) | 29 | $2,213 | $74 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,843 | $102 |
| Anticoagulant management of patient taking warfarin | 42 | $1,821 | $11 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 38 | $1,756 | $27 |
| External shock to heart to regulate heart beat | 15 | $1,561 | $104 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 32 | $1,459 | $28 |
| Programming of single lead pacemaker system | 12 | $997 | $62 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $884 | $74 |
| Blood test, clotting time | 29 | $543 | $4 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 23 | $523 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 21 | $464 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 40 | $314 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $310 | $17 |
| Infusion, normal saline solution, 250 cc | 24 | $94 | None |
2019: 29 services
| Return visit (30+ min) | 626 | $144,765 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 331 | $67,443 | $199 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 79 | $39,819 | $504 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 165 | $32,095 | $177 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 40 | $30,774 | $769 |
| Critical care, first 30-74 minutes | 41 | $19,454 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 116 | $18,051 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 79 | $15,122 | $96 |
| New patient visit (45+ min) | 97 | $13,576 | $140 |
| Long return visit (40+ min) | 89 | $13,561 | $138 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 188 | $13,454 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 169 | $11,892 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $11,278 | $90 |
| New patient visit (60+ min) | 44 | $8,324 | $189 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 46 | $7,636 | $21 |
| Injection, regadenoson, 0.1 mg | 39 | $6,986 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 314 | $6,092 | $16 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 17 | $4,434 | $261 |
| Programming of dual lead pacemaker system | 41 | $3,917 | $57 |
| Ultrasound of heart with probe in esophagus, with report | 35 | $3,908 | $100 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $3,339 | $73 |
| External shock to heart to regulate heart beat | 18 | $2,140 | $102 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $2,128 | $85 |
| Blood test, clotting time | 45 | $1,549 | $4 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 124 | $1,029 | $8 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 38 | $905 | $24 |
| Ultrasound of heart blood flow, valves and chambers | 35 | $660 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $244 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $178 | $14 |
2018: 29 services
| Return visit (30+ min) | 567 | $121,886 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 305 | $62,264 | $199 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 75 | $36,622 | $488 |
| New patient visit (45+ min) | 235 | $32,806 | $140 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 164 | $31,702 | $174 |
| Critical care, first 30-74 minutes | 41 | $19,584 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 115 | $19,216 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $15,640 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 201 | $13,771 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 75 | $13,744 | $92 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 14 | $10,697 | $764 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 130 | $8,417 | $61 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | $7,069 | $20 |
| Injection, regadenoson, 0.1 mg | 35 | $6,074 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 260 | $4,883 | $16 |
| Short return visit (20+ min) | 62 | $4,248 | $62 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 16 | $3,991 | $249 |
| External shock to heart to regulate heart beat | 26 | $3,127 | $95 |
| Programming of dual lead pacemaker system | 41 | $3,124 | $49 |
| Ultrasound of heart with probe in esophagus, with report | 30 | $2,904 | $91 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 13 | $2,859 | $220 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 34 | $2,841 | $84 |
| Long return visit (40+ min) | 19 | $2,516 | $126 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 29 | $1,973 | $68 |
| Blood test, clotting time | 48 | $1,501 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 121 | $1,055 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 29 | $489 | $16 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 17 | $387 | $23 |
| Insertion of needle into vein for collection of blood sample | 13 | $41 | $3 |
2017: 25 services
| Return visit (30+ min) | 436 | $92,906 | $88 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 157 | $34,718 | $220 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $23,354 | $487 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 124 | $23,201 | $173 |
| Critical care, first 30-74 minutes | 35 | $22,242 | $188 |
| New patient visit (45+ min) | 115 | $15,948 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 101 | $14,682 | $62 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 49 | $9,087 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $8,934 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $8,710 | $90 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 37 | $5,807 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 84 | $5,694 | $65 |
| Injection, regadenoson, 0.1 mg | 21 | $3,644 | None |
| Short return visit (20+ min) | 49 | $3,369 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 152 | $2,731 | $15 |
| Programming of dual lead pacemaker system | 30 | $2,437 | $48 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $2,232 | $83 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $2,128 | $69 |
| Blood test, clotting time | 40 | $1,932 | $5 |
| Long return visit (40+ min) | 14 | $1,820 | $114 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,611 | $95 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 160 | $1,323 | $7 |
| Ultrasound of heart | 16 | $980 | $61 |
| Ultrasound of heart blood flow, valves and chambers | 17 | $272 | $16 |
| Insertion of needle into vein for collection of blood sample | 43 | $141 | $3 |
2016: 24 services
| Return visit (30+ min) | 376 | $106,530 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 53 | $26,095 | $492 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $25,773 | $222 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 109 | $21,198 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $15,607 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $12,476 | $63 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 53 | $10,114 | $95 |
| New patient visit (45+ min) | 74 | $10,029 | $136 |
| Critical care, first 30-74 minutes | 25 | $8,837 | $188 |
| Ultrasound of heart | 65 | $7,567 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 107 | $6,233 | $56 |
| Injection, regadenoson, 0.1 mg | 35 | $5,920 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 85 | $5,728 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 45 | $5,269 | $18 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $3,205 | $70 |
| Programming of dual lead pacemaker system | 31 | $2,750 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 136 | $2,610 | $15 |
| Long return visit (40+ min) | 19 | $2,253 | $113 |
| Short return visit (20+ min) | 27 | $2,018 | $67 |
| Blood test, clotting time | 42 | $1,832 | $5 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,478 | $106 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $1,171 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 126 | $979 | $7 |
| Insertion of needle into vein for collection of blood sample | 48 | $176 | $3 |
2015: 26 services
| Return visit (30+ min) | 343 | $97,606 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $24,738 | $221 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 47 | $23,350 | $497 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $20,567 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 123 | $20,208 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 103 | $18,199 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 47 | $12,420 | $132 |
| New patient visit (60+ min) | 54 | $9,842 | $182 |
| Long return visit (40+ min) | 57 | $7,602 | $127 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $6,455 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 98 | $5,731 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 62 | $4,498 | $66 |
| Injection, regadenoson, 0.1 mg | 25 | $4,154 | None |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $4,003 | $70 |
| Programming of dual lead pacemaker system | 33 | $3,081 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 119 | $2,588 | $16 |
| Blood test, clotting time | 51 | $2,206 | $5 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,854 | $109 |
| Ultrasound of heart | 14 | $1,751 | $125 |
| External shock to heart to regulate heart beat | 13 | $1,563 | $112 |
| Short return visit (20+ min) | 21 | $1,374 | $65 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $920 | $77 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 102 | $857 | $8 |
| Programming of single lead pacemaker system | 11 | $650 | $43 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $266 | $17 |
| Insertion of needle into vein for collection of blood sample | 47 | $176 | $3 |
2014: 24 services
| Return visit (30+ min) | 337 | $101,956 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 138 | $31,440 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 109 | $22,735 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $19,996 | $488 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $17,932 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $11,094 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 41 | $10,810 | $132 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 70 | $10,117 | $18 |
| New patient visit (60+ min) | 45 | $8,409 | $187 |
| Long return visit (40+ min) | 57 | $7,607 | $123 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $6,143 | $56 |
| Short return visit (20+ min) | 60 | $4,432 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 63 | $4,416 | $64 |
| Blood test, clotting time | 64 | $3,286 | $5 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $3,218 | $268 |
| Programming of dual lead pacemaker system | 31 | $2,819 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 134 | $2,611 | $15 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 34 | $2,202 | $65 |
| Injection, regadenoson, 0.1 mg | 12 | $1,995 | None |
| Hospital discharge day management, more than 30 minutes | 16 | $1,545 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,501 | $94 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,444 | $76 |
| Insertion of needle into vein for collection of blood sample | 76 | $341 | $3 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $265 | $17 |
2013: 27 services
| Return visit (30+ min) | 302 | $82,389 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 170 | $32,454 | $184 |
| New patient visit (60+ min) | 173 | $29,172 | $169 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $28,334 | $515 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $23,647 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 129 | $23,541 | $172 |
| Long return visit (40+ min) | 99 | $16,675 | $129 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 55 | $14,546 | $132 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 78 | $11,558 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $10,263 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 119 | $6,644 | $54 |
| Injection, regadenoson, 0.1 mg | 34 | $5,753 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 73 | $5,589 | $70 |
| Blood test, clotting time | 69 | $3,689 | $5 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $3,386 | $226 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 137 | $3,111 | $17 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $2,795 | $68 |
| Short return visit (20+ min) | 37 | $2,553 | $67 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $2,353 | $87 |
| Programming of dual lead pacemaker system | 22 | $2,276 | $53 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,792 | $85 |
| External shock to heart to regulate heart beat | 11 | $1,162 | $106 |
| Insertion of needle into vein for collection of blood sample | 76 | $329 | $3 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $322 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 33 | $257 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $212 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $141 | $13 |
Medicaid work
$301 in 2024
Medicaid paid $301 for 68 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 13 | $163 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 39 | $138 |
| Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes | 16 | $0 |
| 2024 | 68 | 3 | 19 | $301 |
| 2023 | 44 | 1 | 17 | $224 |
| 2022 | 12 | 1 | 12 | $62 |
| 2019 | 16 | 1 | 12 | $64 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 44 | $224 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 12 | $62 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 16 | $64 |
Drugs they prescribed that Part D paid
$1,261,612
Pharmacies billed $1,261,612 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 7,284) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
6,294 generic and 990 brand-name prescriptions · $1,261,612 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 431 | $594,577 | $1,380 |
| Xarelto | 171 | $217,455 | $1,272 |
| Farxiga | 87 | $106,240 | $1,221 |
| Jardiance | 50 | $65,607 | $1,312 |
| Repatha Sureclick | 69 | $62,546 | $906 |
See all 67 drugs
| Eliquis | 431 | $594,577 | $1,380 |
| Xarelto | 171 | $217,455 | $1,272 |
| Farxiga | 87 | $106,240 | $1,221 |
| Jardiance | 50 | $65,607 | $1,312 |
| Repatha Sureclick | 69 | $62,546 | $906 |
| Entresto | 21 | $35,001 | $1,667 |
| Brilinta | 18 | $16,531 | $918 |
| Ranolazine Er | 111 | $15,312 | $138 |
| Metoprolol | 614 | $10,321 | $17 |
| Losartan | 740 | $8,919 | $12 |
| Nebivolol | 69 | $7,460 | $108 |
| Dapagliflozin | 12 | $6,858 | $571 |
| Diltiazem 12hr Er | 23 | $5,620 | $244 |
| Atorvastatin | 435 | $4,968 | $11 |
| Sotalol | 208 | $4,899 | $24 |
| Amlodipine Besylate | 446 | $4,719 | $11 |
| Flecainide Acetate | 115 | $4,675 | $41 |
| Rosuvastatin | 303 | $4,510 | $15 |
| Hydralazine | 132 | $3,165 | $24 |
| Amiodarone | 83 | $3,044 | $37 |
| Furosemide | 364 | $3,034 | $8 |
| Ezetimibe | 88 | $2,877 | $33 |
| Spironolactone | 289 | $2,765 | $10 |
| Isosorbide Mononitrate Er | 118 | $2,331 | $20 |
| Diltiazem 24hr Er (Xr) | 58 | $2,325 | $40 |
| Lisinopril | 224 | $2,276 | $10 |
| Midodrine | 37 | $2,100 | $57 |
| Isosorbide Dinitrate | 43 | $2,094 | $49 |
| Potassium Chloride | 91 | $2,056 | $23 |
| Clopidogrel | 124 | $1,975 | $16 |
| Hydrochlorothiazide | 223 | $1,626 | $7 |
| Warfarin | 111 | $1,610 | $15 |
| Diltiazem 24hr Er (Cd) | 49 | $1,481 | $30 |
| Losartan-Hydrochlorothiazide | 86 | $1,438 | $17 |
| Dilt-Xr | 27 | $1,324 | $49 |
| Bumetanide | 42 | $1,323 | $31 |
| Metoprolol | 141 | $1,281 | $9 |
| Digoxin | 46 | $1,059 | $23 |
| Valsartan | 29 | $1,019 | $35 |
| Eplerenone | 12 | $1,004 | $84 |
| Carvedilol | 77 | $968 | $13 |
| Spironolactone-Hctz | 26 | $926 | $36 |
| Pravastatin | 60 | $877 | $15 |
| Diltiazem 24hr Er | 36 | $866 | $24 |
| Prazosin | 41 | $849 | $21 |
| Chlorthalidone | 30 | $755 | $25 |
| Nitroglycerin | 21 | $729 | $35 |
| Verapamil Er | 21 | $636 | $30 |
| Irbesartan | 37 | $555 | $15 |
| Propranolol | 16 | $509 | $32 |
| Ramipril | 24 | $488 | $20 |
| Clonidine | 46 | $440 | $10 |
| Labetalol | 18 | $436 | $24 |
| Simvastatin | 37 | $433 | $12 |
| Olmesartan Medoxomil | 20 | $394 | $20 |
| Valsartan-Hydrochlorothiazide | 13 | $309 | $24 |
| Atenolol | 56 | $299 | $5 |
| Bisoprolol | 15 | $290 | $19 |
| Benazepril | 21 | $266 | $13 |
| Diltiazem | 19 | $245 | $13 |
| Triamterene-Hydrochlorothiazid | 27 | $215 | $8 |
| Metolazone | 15 | $208 | $14 |
| Klor-Con 10 | 13 | $171 | $13 |
| Enalapril Maleate | 14 | $143 | $10 |
| Lisinopril-Hydrochlorothiazide | 23 | $139 | $6 |
| Verapamil | 14 | $125 | $9 |
| Fosinopril | 14 | $95 | $7 |
Year by year
| 2024 | 7,284 | 848 | 0% (0) | 14% | $1,261,612 |
| 2023 | 7,261 | 825 | 0% (0) | 12% | $1,157,798 |
| 2022 | 7,211 | 798 | 0% (0) | None | $1,080,907 |
| 2021 | 6,819 | 778 | 0% (0) | 15% | $987,607 |
| 2020 | 5,856 | 707 | 0% (0) | 16% | $733,831 |
| 2019 | 5,337 | 602 | 0% (0) | 17% | $664,138 |
| 2018 | 4,699 | 549 | None | None | $544,468 |
| 2017 | 3,735 | 393 | 0% (0) | 22% | $357,694 |
| 2016 | 3,365 | 339 | None | 24% | $263,843 |
| 2015 | 2,947 | 290 | 0% (0) | 25% | $229,168 |
| 2014 | 2,630 | 271 | None | 26% | $207,348 |
| 2013 | 1,556 | 210 | 0% (0) | 27% | $112,116 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 68 drugs
| Eliquis | 351 | $509,835 | $1,453 |
| Xarelto | 183 | $218,446 | $1,194 |
| Farxiga | 72 | $84,124 | $1,168 |
| Repatha Sureclick | 64 | $66,055 | $1,032 |
| Entresto | 22 | $34,547 | $1,570 |
| Ranolazine Er | 125 | $24,794 | $198 |
| Jardiance | 24 | $24,358 | $1,015 |
| Metoprolol | 653 | $14,529 | $22 |
| Losartan | 735 | $12,394 | $17 |
| Flecainide Acetate | 118 | $7,505 | $64 |
| Nebivolol | 51 | $7,165 | $140 |
| Diltiazem 12hr Er | 22 | $6,565 | $298 |
| Rosuvastatin | 288 | $6,558 | $23 |
| Atorvastatin | 450 | $6,303 | $14 |
| Sotalol | 193 | $4,642 | $24 |
| Amlodipine Besylate | 420 | $4,544 | $11 |
| Ezetimibe | 65 | $4,258 | $66 |
| Diltiazem 24hr Er (Xr) | 69 | $4,092 | $59 |
| Hydralazine | 141 | $4,039 | $29 |
| Isosorbide Dinitrate | 52 | $3,382 | $65 |
| Isosorbide Mononitrate Er | 145 | $3,372 | $23 |
| Prazosin | 48 | $3,269 | $68 |
| Furosemide | 367 | $2,981 | $8 |
| Diltiazem 24hr Er (Cd) | 71 | $2,913 | $41 |
| Warfarin | 153 | $2,850 | $19 |
| Spironolactone | 312 | $2,752 | $9 |
| Valsartan | 39 | $2,506 | $64 |
| Amiodarone | 80 | $2,476 | $31 |
| Potassium Chloride | 85 | $2,329 | $27 |
| Verapamil Sr | 22 | $2,254 | $102 |
| Diltiazem 24hr Er | 51 | $2,186 | $43 |
| Lisinopril | 202 | $2,158 | $11 |
| Midodrine | 27 | $2,129 | $79 |
| Clopidogrel | 116 | $2,090 | $18 |
| Carvedilol | 80 | $1,800 | $22 |
| Digoxin | 50 | $1,726 | $35 |
| Hydrochlorothiazide | 240 | $1,510 | $6 |
| Bumetanide | 34 | $1,506 | $44 |
| Losartan-Hydrochlorothiazide | 56 | $1,329 | $24 |
| Verapamil Er | 23 | $1,162 | $51 |
| Pravastatin | 65 | $1,102 | $17 |
| Metoprolol | 142 | $1,094 | $8 |
| Dilt-Xr | 15 | $925 | $62 |
| Eplerenone | 11 | $891 | $81 |
| Propranolol | 26 | $774 | $30 |
| Propranolol Hcl Er | 15 | $727 | $48 |
| Nitroglycerin | 25 | $704 | $28 |
| Irbesartan | 21 | $652 | $31 |
| Olmesartan Medoxomil | 24 | $619 | $26 |
| Spironolactone-Hctz | 14 | $595 | $42 |
| Verapamil | 13 | $595 | $46 |
| Diltiazem | 25 | $584 | $23 |
| Labetalol | 17 | $572 | $34 |
| Clonidine | 51 | $560 | $11 |
| Simvastatin | 43 | $546 | $13 |
| Atenolol | 60 | $541 | $9 |
| Valsartan-Hydrochlorothiazide | 19 | $540 | $28 |
| Chlorthalidone | 23 | $518 | $23 |
| Ramipril | 26 | $479 | $18 |
| Metolazone | 15 | $436 | $29 |
| Benazepril | 22 | $428 | $19 |
| Bisoprolol | 16 | $415 | $26 |
| Triamterene-Hydrochlorothiazid | 38 | $412 | $11 |
| Allopurinol | 17 | $375 | $22 |
| Lovastatin | 15 | $238 | $16 |
| Doxazosin Mesylate | 11 | $223 | $20 |
| Lisinopril-Hydrochlorothiazide | 13 | $89 | $7 |
| Fosinopril | 12 | $42 | $4 |
2022: 66 drugs
| Eliquis | 405 | $513,520 | $1,268 |
| Xarelto | 165 | $196,727 | $1,192 |
| Repatha Sureclick | 63 | $65,941 | $1,047 |
| Farxiga | 47 | $47,327 | $1,007 |
| Entresto | 17 | $22,031 | $1,296 |
| Ranolazine Er | 79 | $16,477 | $209 |
| Metoprolol | 634 | $15,459 | $24 |
| Brilinta | 21 | $14,630 | $697 |
| Losartan | 705 | $11,076 | $16 |
| Flecainide Acetate | 106 | $8,910 | $84 |
| Rosuvastatin | 247 | $8,777 | $36 |
| Nebivolol | 55 | $7,938 | $144 |
| Atorvastatin | 448 | $6,786 | $15 |
| Sotalol | 184 | $6,391 | $35 |
| Amiodarone | 113 | $5,413 | $48 |
| Diltiazem 12hr Er | 14 | $4,853 | $347 |
| Amlodipine Besylate | 444 | $4,818 | $11 |
| Hydralazine | 134 | $4,785 | $36 |
| Valsartan | 35 | $4,027 | $115 |
| Ezetimibe | 54 | $3,934 | $73 |
| Isosorbide Mononitrate Er | 149 | $3,780 | $25 |
| Prazosin | 51 | $3,575 | $70 |
| Diltiazem 24hr Er (Xr) | 52 | $3,479 | $67 |
| Warfarin | 164 | $3,444 | $21 |
| Furosemide | 416 | $3,419 | $8 |
| Digoxin | 84 | $3,243 | $39 |
| Spironolactone | 307 | $3,071 | $10 |
| Verapamil Er | 29 | $2,362 | $81 |
| Lisinopril | 195 | $2,321 | $12 |
| Bumetanide | 25 | $2,313 | $93 |
| Potassium Chloride | 93 | $2,280 | $25 |
| Clopidogrel | 111 | $2,277 | $21 |
| Prasugrel | 12 | $2,269 | $189 |
| Diltiazem 24hr Er (Cd) | 70 | $2,177 | $31 |
| Carvedilol | 115 | $2,036 | $18 |
| Midodrine | 21 | $2,019 | $96 |
| Dilt-Xr | 37 | $2,010 | $54 |
| Hydrochlorothiazide | 228 | $1,812 | $8 |
| Isosorbide Dinitrate | 28 | $1,636 | $58 |
| Diltiazem 24hr Er | 30 | $1,501 | $50 |
| Pravastatin | 65 | $1,080 | $17 |
| Metoprolol | 155 | $1,038 | $7 |
| Fludrocortisone Acetate | 11 | $1,018 | $93 |
| Olmesartan Medoxomil | 27 | $979 | $36 |
| Nitroglycerin | 34 | $935 | $28 |
| Irbesartan | 16 | $933 | $58 |
| Chlorthalidone | 26 | $930 | $36 |
| Metolazone | 22 | $924 | $42 |
| Valsartan-Hydrochlorothiazide | 17 | $842 | $50 |
| Simvastatin | 58 | $842 | $15 |
| Losartan-Hydrochlorothiazide | 46 | $772 | $17 |
| Diltiazem | 35 | $752 | $21 |
| Atenolol | 62 | $482 | $8 |
| Verapamil | 13 | $462 | $36 |
| Benazepril | 32 | $427 | $13 |
| Ramipril | 20 | $426 | $21 |
| Triamterene-Hydrochlorothiazid | 27 | $380 | $14 |
| Doxazosin Mesylate | 12 | $344 | $29 |
| Enalapril Maleate | 11 | $327 | $30 |
| Propranolol | 17 | $325 | $19 |
| Bisoprolol | 15 | $319 | $21 |
| Pantoprazole | 24 | $254 | $11 |
| Clonidine | 33 | $243 | $7 |
| Levothyroxine | 11 | $210 | $19 |
| Lovastatin | 14 | $159 | $11 |
| Fosinopril | 12 | $43 | $4 |
2021: 62 drugs
| Eliquis | 409 | $485,978 | $1,188 |
| Xarelto | 189 | $194,994 | $1,032 |
| Repatha Sureclick | 45 | $32,939 | $732 |
| Bystolic | 44 | $25,569 | $581 |
| Entresto | 11 | $18,469 | $1,679 |
| Metoprolol | 566 | $15,706 | $28 |
| Losartan | 640 | $11,861 | $19 |
| Flecainide Acetate | 97 | $8,850 | $91 |
| Atorvastatin | 441 | $7,391 | $17 |
| Rosuvastatin | 190 | $6,825 | $36 |
| Amiodarone | 112 | $5,376 | $48 |
| Amlodipine Besylate | 445 | $5,246 | $12 |
| Dilt-Xr | 67 | $5,123 | $76 |
| Sotalol | 164 | $5,115 | $31 |
| Ranolazine Er | 37 | $4,971 | $134 |
| Nebivolol | 15 | $4,783 | $319 |
| Prazosin | 49 | $4,407 | $90 |
| Isosorbide Dinitrate | 42 | $4,014 | $96 |
| Diltiazem 12hr Er | 12 | $3,790 | $316 |
| Ezetimibe | 42 | $3,788 | $90 |
| Digoxin | 91 | $3,787 | $42 |
| Valsartan | 30 | $3,738 | $125 |
| Furosemide | 437 | $3,736 | $9 |
| Hydralazine | 125 | $3,705 | $30 |
| Diltiazem 24hr Er (Cd) | 69 | $3,405 | $49 |
| Warfarin | 145 | $3,100 | $21 |
| Potassium Chloride | 88 | $3,097 | $35 |
| Spironolactone | 296 | $3,036 | $10 |
| Bumetanide | 28 | $2,947 | $105 |
| Isosorbide Mononitrate Er | 112 | $2,680 | $24 |
| Verapamil Er | 25 | $2,551 | $102 |
| Lisinopril | 222 | $2,156 | $10 |
| Carvedilol | 115 | $2,143 | $19 |
| Eplerenone | 15 | $2,037 | $136 |
| Hydrochlorothiazide | 225 | $1,892 | $8 |
| Clopidogrel | 97 | $1,790 | $18 |
| Diltiazem 24hr Er | 27 | $1,632 | $60 |
| Metolazone | 31 | $1,465 | $47 |
| Metoprolol | 145 | $1,392 | $10 |
| Nitroglycerin | 36 | $1,335 | $37 |
| Olmesartan-Hydrochlorothiazide | 12 | $1,115 | $93 |
| Labetalol | 12 | $1,001 | $83 |
| Olmesartan Medoxomil | 22 | $985 | $45 |
| Chlorthalidone | 26 | $977 | $38 |
| Simvastatin | 79 | $924 | $12 |
| Bisoprolol | 28 | $916 | $33 |
| Pravastatin | 48 | $896 | $19 |
| Losartan-Hydrochlorothiazide | 30 | $874 | $29 |
| Midodrine | 24 | $798 | $33 |
| Diltiazem | 32 | $762 | $24 |
| Pantoprazole | 40 | $708 | $18 |
| Enalapril Maleate | 13 | $660 | $51 |
| Irbesartan | 15 | $647 | $43 |
| Propranolol | 23 | $534 | $23 |
| Atenolol | 49 | $501 | $10 |
| Levothyroxine | 16 | $386 | $24 |
| Benazepril | 27 | $314 | $12 |
| Triamterene-Hydrochlorothiazid | 32 | $291 | $9 |
| Ramipril | 14 | $291 | $21 |
| Lovastatin | 11 | $247 | $22 |
| Clonidine | 26 | $200 | $8 |
| Fosinopril | 11 | $42 | $4 |
2020: 59 drugs
| Eliquis | 338 | $344,734 | $1,020 |
| Xarelto | 139 | $139,748 | $1,005 |
| Bystolic | 51 | $24,152 | $474 |
| Brilinta | 25 | $20,253 | $810 |
| Repatha Sureclick | 20 | $14,281 | $714 |
| Metoprolol | 424 | $12,602 | $30 |
| Losartan | 516 | $10,085 | $20 |
| Ranolazine Er | 26 | $9,310 | $358 |
| Atorvastatin | 383 | $7,191 | $19 |
| Flecainide Acetate | 81 | $6,526 | $81 |
| Rosuvastatin | 139 | $6,419 | $46 |
| Diltiazem 24hr Er (Cd) | 106 | $5,665 | $53 |
| Repatha Pushtronex | 11 | $5,281 | $480 |
| Sotalol | 141 | $4,697 | $33 |
| Potassium Chloride | 113 | $4,429 | $39 |
| Prazosin | 53 | $4,356 | $82 |
| Hydralazine | 134 | $4,194 | $31 |
| Warfarin | 142 | $3,909 | $28 |
| Ezetimibe | 40 | $3,655 | $91 |
| Amlodipine Besylate | 354 | $3,504 | $10 |
| Digoxin | 83 | $3,435 | $41 |
| Furosemide | 368 | $3,165 | $9 |
| Amiodarone | 73 | $3,080 | $42 |
| Isosorbide Mononitrate Er | 89 | $2,562 | $29 |
| Valsartan | 16 | $2,507 | $157 |
| Hydrochlorothiazide | 248 | $2,501 | $10 |
| Bumetanide | 23 | $2,448 | $106 |
| Dilt-Xr | 32 | $2,181 | $68 |
| Spironolactone | 186 | $2,129 | $11 |
| Midodrine | 28 | $2,065 | $74 |
| Diltiazem 24hr Er | 38 | $1,942 | $51 |
| Lisinopril | 233 | $1,939 | $8 |
| Eplerenone | 11 | $1,824 | $166 |
| Olmesartan Medoxomil | 29 | $1,597 | $55 |
| Fludrocortisone Acetate | 24 | $1,550 | $65 |
| Losartan-Hydrochlorothiazide | 27 | $1,540 | $57 |
| Carvedilol | 95 | $1,531 | $16 |
| Nitroglycerin | 26 | $1,476 | $57 |
| Metolazone | 22 | $1,327 | $60 |
| Clopidogrel | 79 | $1,227 | $16 |
| Verapamil Er | 23 | $1,153 | $50 |
| Labetalol | 16 | $1,094 | $68 |
| Metoprolol | 154 | $1,053 | $7 |
| Propranolol | 27 | $1,025 | $38 |
| Pravastatin | 37 | $1,017 | $27 |
| Valsartan-Hydrochlorothiazide | 15 | $988 | $66 |
| Levothyroxine | 35 | $892 | $25 |
| Chlorthalidone | 22 | $878 | $40 |
| Simvastatin | 77 | $794 | $10 |
| Bisoprolol | 22 | $785 | $36 |
| Pantoprazole | 62 | $659 | $11 |
| Lovastatin | 16 | $635 | $40 |
| Triamterene-Hydrochlorothiazid | 36 | $480 | $13 |
| Atenolol | 26 | $420 | $16 |
| Diltiazem | 17 | $418 | $25 |
| Benazepril | 28 | $338 | $12 |
| Ramipril | 14 | $302 | $22 |
| Lisinopril-Hydrochlorothiazide | 16 | $221 | $14 |
| Clonidine | 17 | $197 | $12 |
2019: 59 drugs
| Eliquis | 297 | $278,322 | $937 |
| Xarelto | 101 | $105,693 | $1,046 |
| Bystolic | 77 | $29,979 | $389 |
| Repatha Sureclick | 15 | $18,106 | $1,207 |
| Brilinta | 26 | $16,308 | $627 |
| Metoprolol | 375 | $13,926 | $37 |
| Ranolazine Er | 18 | $10,411 | $578 |
| Diltiazem 24hr Er (Cd) | 116 | $8,288 | $71 |
| Entresto | 14 | $7,536 | $538 |
| Atorvastatin | 366 | $7,423 | $20 |
| Losartan | 376 | $7,250 | $19 |
| Rosuvastatin | 107 | $5,482 | $51 |
| Hydralazine | 151 | $5,364 | $36 |
| Valsartan | 22 | $5,110 | $232 |
| Prazosin | 50 | $4,599 | $92 |
| Flecainide Acetate | 56 | $4,491 | $80 |
| Amlodipine Besylate | 338 | $4,353 | $13 |
| Sotalol | 117 | $4,242 | $36 |
| Warfarin | 157 | $3,931 | $25 |
| Digoxin | 76 | $3,882 | $51 |
| Furosemide | 385 | $3,757 | $10 |
| Potassium Chloride | 74 | $3,303 | $45 |
| Isosorbide Mononitrate Er | 93 | $3,263 | $35 |
| Dilt-Xr | 36 | $2,620 | $73 |
| Amiodarone | 91 | $2,553 | $28 |
| Bumetanide | 17 | $2,323 | $137 |
| Hydrochlorothiazide | 200 | $2,066 | $10 |
| Ezetimibe | 25 | $2,054 | $82 |
| Spironolactone | 141 | $1,998 | $14 |
| Lisinopril | 199 | $1,733 | $9 |
| Carvedilol | 103 | $1,660 | $16 |
| Cartia Xt | 28 | $1,646 | $59 |
| Midodrine | 17 | $1,455 | $86 |
| Metolazone | 24 | $1,377 | $57 |
| Labetalol | 12 | $1,352 | $113 |
| Olmesartan Medoxomil | 25 | $1,266 | $51 |
| Levothyroxine | 44 | $1,257 | $29 |
| Metoprolol | 136 | $1,161 | $9 |
| Propranolol | 26 | $1,119 | $43 |
| Clopidogrel | 80 | $1,042 | $13 |
| Simvastatin | 90 | $1,029 | $11 |
| Pravastatin | 37 | $918 | $25 |
| Nitroglycerin | 25 | $843 | $34 |
| Diltiazem 24hr Er | 16 | $818 | $51 |
| Pantoprazole | 58 | $754 | $13 |
| Triamterene-Hydrochlorothiazid | 48 | $683 | $14 |
| Digox | 14 | $670 | $48 |
| Losartan-Hydrochlorothiazide | 28 | $567 | $20 |
| Atenolol | 39 | $557 | $14 |
| Lovastatin | 15 | $514 | $34 |
| Fludrocortisone Acetate | 12 | $499 | $42 |
| Ramipril | 11 | $458 | $42 |
| Torsemide | 13 | $445 | $34 |
| Omega-3 Acid Ethyl Esters | 11 | $441 | $40 |
| Benazepril | 34 | $411 | $12 |
| Valsartan-Hydrochlorothiazide | 12 | $362 | $30 |
| Allopurinol | 11 | $318 | $29 |
| Clonidine | 20 | $273 | $14 |
| Lisinopril-Hydrochlorothiazide | 14 | $138 | $10 |
2018: 55 drugs
| Eliquis | 255 | $216,568 | $849 |
| Xarelto | 73 | $72,342 | $991 |
| Bystolic | 69 | $20,840 | $302 |
| Ranexa | 15 | $20,597 | $1,373 |
| Repatha Pushtronex | 16 | $19,637 | $1,227 |
| Repatha Sureclick | 12 | $17,204 | $1,434 |
| Metoprolol | 356 | $14,084 | $40 |
| Brilinta | 20 | $13,163 | $658 |
| Atorvastatin | 317 | $6,693 | $21 |
| Prasugrel | 16 | $5,764 | $360 |
| Losartan | 335 | $5,548 | $17 |
| Prazosin | 56 | $5,452 | $97 |
| Flecainide Acetate | 58 | $4,697 | $81 |
| Valsartan | 30 | $4,116 | $137 |
| Digoxin | 49 | $3,979 | $81 |
| Diltiazem 24hr Er (Cd) | 72 | $3,933 | $55 |
| Warfarin | 173 | $3,894 | $23 |
| Amiodarone | 98 | $3,743 | $38 |
| Rosuvastatin | 82 | $3,686 | $45 |
| Amlodipine Besylate | 302 | $3,296 | $11 |
| Potassium Chloride | 85 | $3,056 | $36 |
| Hydralazine | 100 | $2,879 | $29 |
| Bumetanide | 30 | $2,779 | $93 |
| Furosemide | 339 | $2,695 | $8 |
| Isosorbide Mononitrate Er | 66 | $2,440 | $37 |
| Ezetimibe | 20 | $2,364 | $118 |
| Sotalol | 74 | $2,292 | $31 |
| Cartia Xt | 43 | $2,211 | $51 |
| Spironolactone | 136 | $1,951 | $14 |
| Midodrine | 25 | $1,845 | $74 |
| Lisinopril | 159 | $1,707 | $11 |
| Carvedilol | 119 | $1,630 | $14 |
| Digox | 24 | $1,475 | $61 |
| Hydrochlorothiazide | 143 | $1,369 | $10 |
| Metolazone | 24 | $1,175 | $49 |
| Clopidogrel | 57 | $1,155 | $20 |
| Simvastatin | 94 | $1,065 | $11 |
| Levothyroxine | 38 | $1,052 | $28 |
| Metoprolol | 116 | $962 | $8 |
| Pantoprazole | 49 | $839 | $17 |
| Pravastatin | 28 | $742 | $26 |
| Ramipril | 16 | $734 | $46 |
| Triamterene-Hydrochlorothiazid | 44 | $678 | $15 |
| Allopurinol | 22 | $595 | $27 |
| Atenolol | 33 | $506 | $15 |
| Propranolol | 11 | $497 | $45 |
| Nitroglycerin | 18 | $481 | $27 |
| Lovastatin | 14 | $458 | $33 |
| Fludrocortisone Acetate | 15 | $363 | $24 |
| Benazepril | 28 | $360 | $13 |
| Valsartan-Hydrochlorothiazide | 12 | $351 | $29 |
| Losartan-Hydrochlorothiazide | 18 | $347 | $19 |
| Verapamil Er | 12 | $289 | $24 |
| Diltiazem | 12 | $288 | $24 |
| Clonidine | 11 | $204 | $19 |
2017: 45 drugs
| Eliquis | 147 | $106,151 | $722 |
| Xarelto | 60 | $44,621 | $744 |
| Ranexa | 17 | $21,006 | $1,236 |
| Bystolic | 57 | $13,998 | $246 |
| Metoprolol | 326 | $13,692 | $42 |
| Brilinta | 20 | $10,282 | $514 |
| Prazosin | 64 | $6,469 | $101 |
| Amiodarone | 66 | $4,460 | $68 |
| Atorvastatin | 196 | $4,365 | $22 |
| Losartan | 272 | $3,854 | $14 |
| Veltassa | 12 | $3,505 | $292 |
| Diltiazem 24hr Er | 63 | $3,436 | $55 |
| Flecainide Acetate | 42 | $2,905 | $69 |
| Warfarin | 196 | $2,801 | $14 |
| Potassium Chloride | 73 | $2,376 | $33 |
| Furosemide | 295 | $2,298 | $8 |
| Amlodipine Besylate | 210 | $2,238 | $11 |
| Valsartan | 36 | $2,217 | $62 |
| Digoxin | 27 | $2,132 | $79 |
| Cartia Xt | 51 | $1,827 | $36 |
| Lisinopril | 156 | $1,762 | $11 |
| Isosorbide Mononitrate Er | 44 | $1,704 | $39 |
| Digox | 21 | $1,696 | $81 |
| Rosuvastatin | 24 | $1,692 | $70 |
| Spironolactone | 104 | $1,660 | $16 |
| Bumetanide | 28 | $1,648 | $59 |
| Levothyroxine | 44 | $1,492 | $34 |
| Hydralazine | 40 | $1,356 | $34 |
| Coumadin | 11 | $1,303 | $118 |
| Sotalol | 72 | $1,282 | $18 |
| Carvedilol | 108 | $1,225 | $11 |
| Metolazone | 25 | $1,193 | $48 |
| Ramipril | 18 | $921 | $51 |
| Pantoprazole | 49 | $854 | $17 |
| Clopidogrel | 55 | $722 | $13 |
| Metoprolol | 77 | $691 | $9 |
| Hydrochlorothiazide | 103 | $643 | $6 |
| Midodrine | 12 | $560 | $47 |
| Triamterene-Hydrochlorothiazid | 37 | $558 | $15 |
| Atenolol | 47 | $512 | $11 |
| Simvastatin | 67 | $476 | $7 |
| Allopurinol | 22 | $444 | $20 |
| Pravastatin | 19 | $407 | $21 |
| Lovastatin | 17 | $394 | $23 |
| Benazepril | 25 | $255 | $10 |
2016: 46 drugs
| Eliquis | 100 | $59,493 | $595 |
| Xarelto | 44 | $30,104 | $684 |
| Ranexa | 17 | $15,543 | $914 |
| Brilinta | 29 | $13,290 | $458 |
| Bystolic | 55 | $11,644 | $212 |
| Metoprolol | 265 | $9,675 | $37 |
| Combivent Respimat | 25 | $8,441 | $338 |
| Benicar Hct | 11 | $6,904 | $628 |
| Pradaxa | 12 | $5,714 | $476 |
| Atorvastatin | 215 | $5,247 | $24 |
| Valsartan | 28 | $3,760 | $134 |
| Prazosin | 49 | $3,565 | $73 |
| Amiodarone | 81 | $3,496 | $43 |
| Losartan | 187 | $2,924 | $16 |
| Amlodipine Besylate | 224 | $2,392 | $11 |
| Warfarin | 186 | $2,349 | $13 |
| Furosemide | 308 | $2,322 | $8 |
| Diltiazem 24hr Er | 46 | $2,043 | $44 |
| Sotalol | 69 | $1,757 | $25 |
| Potassium Chloride | 57 | $1,705 | $30 |
| Lisinopril | 147 | $1,690 | $11 |
| Metolazone | 39 | $1,671 | $43 |
| Spironolactone | 102 | $1,436 | $14 |
| Levothyroxine | 47 | $1,415 | $30 |
| Isosorbide Mononitrate Er | 35 | $1,327 | $38 |
| Flecainide Acetate | 26 | $1,250 | $48 |
| Labetalol | 14 | $1,174 | $84 |
| Digoxin | 21 | $1,151 | $55 |
| Digox | 20 | $1,054 | $53 |
| Carvedilol | 76 | $1,011 | $13 |
| Clopidogrel | 70 | $942 | $13 |
| Metoprolol | 93 | $812 | $9 |
| Cartia Xt | 28 | $697 | $25 |
| Bumetanide | 19 | $694 | $37 |
| Hydrochlorothiazide | 89 | $660 | $7 |
| Hydralazine | 17 | $526 | $31 |
| Simvastatin | 65 | $514 | $8 |
| Propranolol | 12 | $503 | $42 |
| Pantoprazole | 32 | $470 | $15 |
| Pravastatin | 17 | $413 | $24 |
| Atenolol | 37 | $400 | $11 |
| Ramipril | 13 | $377 | $29 |
| Fluticasone Propionate | 20 | $267 | $13 |
| Benazepril | 21 | $223 | $11 |
| Triamterene-Hydrochlorothiazid | 15 | $191 | $13 |
| Allopurinol | 12 | $171 | $14 |
2015: 49 drugs
| Eliquis | 66 | $40,779 | $618 |
| Xarelto | 72 | $32,579 | $452 |
| Bystolic | 43 | $13,672 | $318 |
| Brilinta | 28 | $11,415 | $408 |
| Valsartan | 53 | $10,740 | $203 |
| Ranexa | 13 | $10,279 | $791 |
| Metoprolol | 215 | $9,676 | $45 |
| Combivent Respimat | 28 | $8,508 | $304 |
| Spiriva | 14 | $6,088 | $435 |
| Atorvastatin | 180 | $4,441 | $25 |
| Advair Diskus | 11 | $4,340 | $395 |
| Amiodarone | 89 | $3,258 | $37 |
| Benicar Hct | 13 | $3,135 | $241 |
| Warfarin | 145 | $2,713 | $19 |
| Crestor | 11 | $2,348 | $213 |
| Potassium Chloride | 72 | $2,335 | $32 |
| Prazosin | 31 | $1,716 | $55 |
| Levothyroxine | 53 | $1,569 | $30 |
| Losartan | 152 | $1,560 | $10 |
| Digoxin | 27 | $1,528 | $57 |
| Furosemide | 223 | $1,510 | $7 |
| Amlodipine Besylate | 152 | $1,471 | $10 |
| Flecainide Acetate | 19 | $1,154 | $61 |
| Labetalol | 11 | $1,087 | $99 |
| Lisinopril | 132 | $1,037 | $8 |
| Cartia Xt | 30 | $1,019 | $34 |
| Carvedilol | 83 | $934 | $11 |
| Spironolactone | 70 | $832 | $12 |
| Bumetanide | 20 | $777 | $39 |
| Clopidogrel | 46 | $745 | $16 |
| Digox | 14 | $738 | $53 |
| Isosorbide Mononitrate Er | 38 | $734 | $19 |
| Hydrochlorothiazide | 69 | $719 | $10 |
| Simvastatin | 62 | $673 | $11 |
| Metolazone | 19 | $665 | $35 |
| Diltiazem 24hr Er | 15 | $647 | $43 |
| Dilt-Xr | 11 | $607 | $55 |
| Metoprolol | 89 | $581 | $7 |
| Sotalol | 47 | $568 | $12 |
| Hydralazine | 26 | $547 | $21 |
| Diltiazem Er | 13 | $504 | $39 |
| Pantoprazole | 30 | $466 | $16 |
| Atenolol | 51 | $445 | $9 |
| Pravastatin | 12 | $340 | $28 |
| Nitrostat | 11 | $334 | $30 |
| Fluticasone Propionate | 30 | $314 | $10 |
| Allopurinol | 11 | $277 | $25 |
| Diltiazem | 13 | $100 | $8 |
| Famotidine | 15 | $84 | $6 |
2014: 49 drugs
| Eliquis | 39 | $20,417 | $524 |
| Xarelto | 45 | $17,272 | $384 |
| Diovan | 37 | $13,738 | $371 |
| Bystolic | 56 | $13,264 | $237 |
| Effient | 18 | $13,236 | $735 |
| Ranexa | 17 | $11,570 | $681 |
| Zetia | 18 | $8,530 | $474 |
| Metoprolol | 154 | $7,826 | $51 |
| Crestor | 16 | $7,690 | $481 |
| Spiriva | 24 | $7,621 | $318 |
| Multaq | 12 | $4,768 | $397 |
| Combivent Respimat | 17 | $4,704 | $277 |
| Benicar | 11 | $4,429 | $403 |
| Valsartan | 15 | $4,131 | $275 |
| Benicar Hct | 13 | $3,778 | $291 |
| Atorvastatin | 126 | $3,480 | $28 |
| Warfarin | 183 | $2,680 | $15 |
| Potassium Chloride | 73 | $2,512 | $34 |
| Digox | 43 | $2,386 | $55 |
| Losartan | 145 | $2,052 | $14 |
| Clopidogrel | 43 | $1,974 | $46 |
| Amiodarone | 64 | $1,719 | $27 |
| Prazosin | 30 | $1,573 | $52 |
| Amlodipine Besylate | 121 | $1,380 | $11 |
| Carvedilol | 81 | $1,299 | $16 |
| Lisinopril | 101 | $1,216 | $12 |
| Spironolactone | 73 | $1,108 | $15 |
| Levothyroxine | 38 | $1,061 | $28 |
| Furosemide | 191 | $1,029 | $5 |
| Isosorbide Mononitrate Er | 36 | $1,017 | $28 |
| Labetalol | 12 | $1,009 | $84 |
| Digoxin | 14 | $929 | $66 |
| Sotalol | 39 | $898 | $23 |
| Pindolol | 14 | $840 | $60 |
| Hydrochlorothiazide | 68 | $682 | $10 |
| Simvastatin | 59 | $659 | $11 |
| Diltiazem 24hr Er | 13 | $658 | $51 |
| Flecainide Acetate | 17 | $608 | $36 |
| Metoprolol | 67 | $593 | $9 |
| Metolazone | 17 | $508 | $30 |
| Hydralazine | 20 | $497 | $25 |
| Atenolol | 40 | $481 | $12 |
| Diltiazem Er | 18 | $458 | $25 |
| Bumetanide | 13 | $342 | $26 |
| Pravastatin | 12 | $308 | $26 |
| Fluticasone Propionate | 21 | $306 | $15 |
| Pantoprazole | 18 | $305 | $17 |
| Famotidine | 19 | $108 | $6 |
| Sertraline | 14 | $81 | $6 |
2013: 30 drugs
| Ranexa | 25 | $13,109 | $524 |
| Diovan | 29 | $12,843 | $443 |
| Benicar | 18 | $7,648 | $425 |
| Bystolic | 36 | $6,963 | $193 |
| Xarelto | 15 | $6,779 | $452 |
| Zetia | 16 | $5,963 | $373 |
| Metoprolol | 90 | $4,948 | $55 |
| Effient | 11 | $3,384 | $308 |
| Atorvastatin | 82 | $3,182 | $39 |
| Warfarin | 145 | $2,266 | $16 |
| Losartan | 90 | $2,075 | $23 |
| Potassium Chloride | 32 | $1,590 | $50 |
| Clopidogrel | 28 | $1,313 | $47 |
| Amlodipine Besylate | 83 | $1,313 | $16 |
| Amiodarone | 43 | $931 | $22 |
| Lisinopril | 83 | $865 | $10 |
| Furosemide | 112 | $725 | $6 |
| Diltiazem 24hr Er | 16 | $706 | $44 |
| Hydralazine | 17 | $631 | $37 |
| Levothyroxine | 33 | $625 | $19 |
| Carvedilol | 37 | $622 | $17 |
| Isosorbide Mononitrate Er | 17 | $573 | $34 |
| Spironolactone | 29 | $541 | $19 |
| Simvastatin | 42 | $471 | $11 |
| Prazosin | 11 | $423 | $38 |
| Metoprolol | 40 | $402 | $10 |
| Hydrochlorothiazide | 42 | $384 | $9 |
| Digox | 29 | $314 | $11 |
| Atenolol | 17 | $126 | $7 |
| Famotidine | 13 | $66 | $5 |
Money from drug and device companies
$988 in 2025
| 2025 | 15 | 36 | None | $988 |
| 2024 | 18 | 85 | None | $1,926 |
| 2023 | 14 | 62 | None | $1,289 |
| 2022 | 10 | 39 | None | $1,003 |
| 2021 | 9 | 42 | None | $832 |
| 2020 | 10 | 19 | None | $412 |
| 2019 | 11 | 51 | None | $881 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik | Amvia Edge | $167 | 1 payment
|
| Amgen | Repatha | $124 | 5 payments
|
| Merck Sharp & Dohme | Verquvo | $123 | 6 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $89 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $85 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $82 | 3 payments
|
See all 36 published payments
| Amgen | Meals · 2025-12-18 | Repatha | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-02 | Farxiga | $19 |
| Alnylam Pharmaceuticals | Meals · 2025-11-20 | Amvuttra | $25 |
| Merck Sharp & Dohme | Meals · 2025-10-21 | Capvaxive | $18 |
| Merck Sharp & Dohme | Meals · 2025-09-30 | Verquvo | $15 |
| Biotronik | Meals · 2025-09-18 | Amvia Edge | $167 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-16 | Kerendia | $25 |
| BridgeBio Pharma | Meals · 2025-09-12 | Attruby | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-04 | Jardiance | $28 |
| Merck Sharp & Dohme | Meals · 2025-08-27 | Verquvo | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-05 | Kerendia | $21 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-29 | Lifevest | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-18 | Farxiga | $26 |
| Amgen | Meals · 2025-07-15 | Repatha | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-12 | Eliquis | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-12 | Camzyos | $22 |
| Boston Scientific | Meals · 2025-05-29 | Watchman Flx | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-23 | Kerendia | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-20 | Jardiance | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-08 | Farxiga | $18 |
| Merck Sharp & Dohme | Meals · 2025-04-28 | Verquvo | $23 |
| Amgen | Meals · 2025-04-24 | Repatha | $22 |
| Amgen | Meals · 2025-04-02 | Repatha | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-01 | Farxiga | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-18 | Eliquis | $16 |
| Pfizer | Meals · 2025-03-13 | Vyndaqel | $27 |
| Novo Nordisk | Meals · 2025-03-12 | Ozempic | $26 |
| Octapharma USA | Meals · 2025-03-07 | Fibryga | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-04 | Jardiance | $20 |
| Edwards Lifesciences | Meals · 2025-02-27 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $47 |
| Merck Sharp & Dohme | Meals · 2025-02-20 | Verquvo | $22 |
| Boston Scientific | Meals · 2025-02-19 | Watchman Flx | $25 |
| Edwards Lifesciences | Meals · 2025-02-13 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $26 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-24 | Kerendia | $20 |
| Amgen | Meals · 2025-01-21 | Repatha | $26 |
| Merck Sharp & Dohme | Meals · 2025-01-08 | Verquvo | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,926
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $227 | 4 payments
|
| Merck Sharp & Dohme | Verquvo | $182 | 8 payments
|
| Novartis Pharmaceuticals | Leqvio | $177 | 9 payments
|
| Amgen | Repatha | $140 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $139 | 7 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $118 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $118 | 6 payments
|
| Boston Scientific | Watchman Flx | $107 | 5 payments
|
| Novo Nordisk | Ozempic | $103 | 5 payments
|
| Lexicon Pharmaceuticals | None | $97 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $95 | 4 payments
|
| Esperion Therapeutics | Nexletol | $86 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $76 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $72 | 2 payments
|
| Heartflow | Ffrct | $72 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $49 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $44 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $23 | 1 payment
|
2023: $1,289
| Merck Sharp & Dohme | Verquvo | $256 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $175 | 8 payments
|
| Novartis Pharmaceuticals | Leqvio | $175 | 8 payments
|
| Janssen Pharmaceuticals | Xarelto | $167 | 7 payments
|
| Amgen | Repatha | $134 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $85 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $72 | 4 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $47 | 2 payments
|
| Boston Scientific | Watchman Flx | $41 | 2 payments
|
| Pfizer | Eliquis | $35 | 2 payments
|
| Lexicon Pharmaceuticals | Inpefa | $35 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $28 | 1 payment
|
| LivaNova USA | Lifesparc | $20 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $20 | 1 payment
|
2022: $1,003
| Merck Sharp & Dohme | Verquvo | $181 | 11 payments
|
| Amgen | Repatha | $167 | 6 payments
|
| Biotronik | Rivacor 7 Dr-T | $159 | 1 payment
|
| Medtronic | Venaseal | $111 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $93 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $93 | 5 payments
|
| Pfizer | Eliquis | $67 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $54 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $48 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $31 | 1 payment
|
2021: $832
| Amgen | Repatha | $242 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $136 | 9 payments
|
| Merck Sharp & Dohme | Verquvo | $127 | 9 payments
|
| Janssen Pharmaceuticals | Xarelto | $84 | 5 payments
|
| Abbott Laboratories | Mitraclip System | $73 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $66 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $62 | 3 payments
|
| Pfizer | Eliquis | $31 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $11 | 1 payment
|
2020: $412
| Amgen | Repatha | $113 | 4 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $56 | 4 payments
|
| Abbott Laboratories | Mitra Clip System | $45 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $44 | 2 payments
|
| Kowa Pharmaceuticals America | Livalo | $42 | 2 payments
|
| Philips Electronics North America | (7999) Src Undivided | $40 | 1 payment
|
| Amarin Pharma | Vascepa | $23 | 1 payment
|
| Lundbeck | Northera | $20 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $13 | 1 payment
|
2019: $881
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $198 | 28 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $195 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $138 | 7 payments
|
| Abiomed | Impella | $125 | 1 payment
|
| Amgen | Corlanor | $55 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $54 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $40 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $22 | 1 payment
|
| Biotronik | None | $20 | 1 payment
|
| Pfizer | Eliquis | $20 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $15 | 1 payment
|
Checkups this office reported
6 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 68.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 53%That's more than half. | 178 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 96%That's most of the people this applied to. Worse on this measure. | 50 |
| Medications listed in the chartVisits where the current medication list was documented | 80%That's most of the people this applied to. | 6,994 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 272 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 14% | 1,189 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 26%That's less than half. | 1,780 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Anticoagulant Management Improvements
Professional record
- NPI
- 1811073323
- Licence
- CA A72494California A72494: Current · expires 2028-04-30
- Trained
- University of Utah School of Medicine, 2010
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 15215 National Ave Ste 105, Los Gatos, CA, 95032
- NPI first listed
- 2006-10-27
- NPI last updated
- 2025-02-06
- NPI record certified
- 2025-02-06
This is when the NPI record was last certified, not a medical board exam.